# HALO catalysts: HALOZYME THERAPEUTICS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/halo/catalysts

> HALOZYME THERAPEUTICS, INC. (HALO) has 2 upcoming catalysts. The next is the testosterone enanthate primary completion, March 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | HALOZYME THERAPEUTICS, INC. |
| Ticker | HALO (Nasdaq) |
| SEC CIK | 1159036 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/halo |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2024 | [Ocrevus® (ocrelizumab) FDA approval](https://sec-api.dev/pdufa/ocrelizumab) | HALO |  | completed, approved | "•In September 2024, Roche announced the U.S. Food and Drug Administration ("FDA") approved OCREVUS ZUNOVO with ENHANZE as a twice a year ten-minute SC injection for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis, and in July 2024 and June 2024, Roche announced the Medicines and Healthcare products Regulatory Agency and European Commission granted marketing authorization in Great Britain and the European Union ("EU"), respectively, for Ocrevus (ocrelizumab) SC for the same indications marking our eight approved partner product with ENHANZE." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1159036/000115903625000010/halo-20241231.htm)) |
| February 18, 2025 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "SAN DIEGO, February 18, 2025 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024, provided an update on its recent corporate activities and reiterated its 2025 financial guidance." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903625000008/ex991q420248-k.htm)) |
| May 2025 | [DARZALEX (daratumumab) FDA advisory committee meeting](https://sec-api.dev/pdufa/daratumumab) | HALO |  | completed, positive | "•In May 2025, Janssen announced the U.S. Food and Drug Administration ("FDA") Oncologic Drug Advisory Committee voted in favor of the benefit-risk profile of DARZALEX FASPRO for the treatment of adult patients with high risk smoldering multiple myeloma." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1159036/000115903625000034/halo-20250630.htm)) |
| May 2025 | [FASPRO (daratumumab-hyaluronidase) FDA advisory committee meeting](https://sec-api.dev/pdufa/daratumumab-hyaluronidase) | HALO |  | completed, positive | "•In May 2025, Janssen announced the U.S. Food and Drug Administration ("FDA") Oncologic Drug Advisory Committee voted in favor of the benefit-risk profile of DARZALEX Faspro® for the treatment of adult patients with high risk SMM." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903625000033/ex991q220258-k.htm)) |
| May 6, 2025 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903625000025/ex991q120258-k.htm)) |
| August 5, 2025 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903625000033/ex991q220258-k.htm)) |
| Nov 2025 | [FASPRO (daratumumab-hyaluronidase) FDA approval](https://sec-api.dev/pdufa/daratumumab-hyaluronidase) | HALO |  | completed, approved | "•In November 2025, Janssen announced the FDA approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) co-formulated with ENHANZE®, as single treatment of adult patients with high-risk smoldering multiple myeloma." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000023/ex991q420258-k.htm)) |
| November 3, 2025 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "SAN DIEGO, November 3, 2025 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the third quarter ended September 30, 2025 and provided an update on its recent corporate activities." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903625000044/ex991q320258-k.htm)) |
| Dec 2025 | [FASPROTM (amivantamab-hyaluronidase) FDA approval](https://sec-api.dev/pdufa/amivantamab-hyaluronidase) | HALO | with epidermal growth factor receptor | completed, approved | "•In December 2025, Janssen announced the FDA approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) for the treatment of patients with epidermal growth factor receptor ("EGFR")-mutated locally advanced or metastatic non-small cell lung cancer ("NSCLC")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000023/ex991q420258-k.htm)) |
| Jan 2026 | [FASPRO (daratumumab-hyaluronidase) FDA approval](https://sec-api.dev/pdufa/daratumumab-hyaluronidase) | HALO |  | completed, approved | "•In January 2026, Janssen announced the FDA approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/ex991q120268-k.htm)) |
| Jan 2026 | [ARGX-124 trial start](https://sec-api.dev/pdufa/argx-124) | HALO |  | completed | "•In January 2026, argenx initiated a Phase 1 study to evaluate ARGX-124 with ENHANZE®." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/ex991q120268-k.htm)) |
| Feb 2026 | [VYVGART (efgartigimod) topline data readout](https://sec-api.dev/pdufa/efgartigimod) | HALO |  | completed, positive | "•In February 2026, argenx announced positive topline results from the Phase 3 ADAPT oculus trial of VYVGART® with ENHANZE® in ocular myasthenia gravis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/ex991q120268-k.htm)) |
| February 17, 2026 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "SAN DIEGO, February 17, 2026 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the full year and fourth quarter ended December 31, 2025, and provided an update on its recent corporate activities." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000023/ex991q420258-k.htm)) |
| Mar 2026 | [TECVAYLI (teclistamab) FDA approval](https://sec-api.dev/pdufa/teclistamab) | HALO | with relapsed or refractory multiple myeloma | completed, approved | "•In March 2026, Janssen announced the FDA approved TECVAYLI® (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/ex991q120268-k.htm)) |
| May 2026 | [RYBREVANT (amivantamab) NDA/BLA submission](https://sec-api.dev/pdufa/amivantamab) | HALO |  | completed | "•In May 2026, Janssen announced pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj delivered durable responses in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy and submitted a supplemental Biologics License Application ("sBLA") to the U.S. Food and Drug Administration ("FDA")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000103/ex991q220268-k.htm)) |
| May 11, 2026 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/ex991q120268-k.htm)) |
| August 6, 2026 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000103/ex991q220268-k.htm)) |
| Oct 2026 | [Tecentriq® (atezolizumab) FDA approval](https://sec-api.dev/pdufa/atezolizumab) | HALO |  | completed, approved | "•In October 2026, Roche announced the FDA has approved TECENTRIQ® (atezolizumab) and TECENTRIQ HYBREZA® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair ("dMMR") colon cancer, a type of tumour characterized by high mutation rates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000143/ex991q320268-k.htm)) |
| November 5, 2026 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000143/ex991q320268-k.htm)) |
| March 2028 | [Testosterone enanthate primary completion](https://sec-api.dev/pdufa/testosterone-enanthate) | HALO | Hypogonadism, Male | scheduled | "NCT06689085 (52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Halozyme Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06689085)) |
| Mar to Jun 2028 | [Testosterone enanthate topline data readout](https://sec-api.dev/pdufa/testosterone-enanthate) | HALO | Hypogonadism, Male | scheduled | "NCT06689085 (52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Halozyme Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06689085)) |

## Drugs

- [FASPROTM (amivantamab-hyaluronidase)](https://sec-api.dev/pdufa/amivantamab-hyaluronidase): with epidermal growth factor receptor
- [ARGX-124](https://sec-api.dev/pdufa/argx-124): 
- [FASPRO (daratumumab-hyaluronidase)](https://sec-api.dev/pdufa/daratumumab-hyaluronidase): 
- [Ocrevus® (ocrelizumab)](https://sec-api.dev/pdufa/ocrelizumab): 
- [Testosterone enanthate](https://sec-api.dev/pdufa/testosterone-enanthate): Hypogonadism, Male

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/halo/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "HALO catalysts: HALOZYME THERAPEUTICS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/halo/catalysts

```bibtex
@misc{secapidev_companies_halo_catalysts_20261116,
  title        = {HALO catalysts: HALOZYME THERAPEUTICS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/halo/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_halo_catalysts_20261116","title":"HALO catalysts: HALOZYME THERAPEUTICS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/halo/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
